Bilateral subdural haematomas following lumbar puncture in three haematopoietic stem cell transplant recipients

Between 1990 and 1996, three patients (1.1%), all with CML, among 272 patients with haematological malignancies, developed bilateral subdural haematomas (SDH) after treatment with i.t. MTX before HSCT in our unit. Since October 1996, we have given i.t. MTX only to patients at increased risk of CNS l...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Bone marrow transplantation (Basingstoke) 1999-11, Vol.24 (9), p.1033-1035
Hauptverfasser:	HENTSCHKE, P, HÄGGLUND, H, MATTSSON, J, CARLENS, S, LÖNNQVIST, B, LJUNGMAN, P, ASCHAN, J, FREDRIKSON, S, RINGDEN, O
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Antimetabolites, Antineoplastic - administration & dosage Antimetabolites, Antineoplastic - adverse effects Antineoplastic agents Biological and medical sciences Bone marrow Combined treatments (chemotherapy of immunotherapy associated with an other treatment) Hematoma, Subdural - diagnostic imaging Hematoma, Subdural - etiology Hematopoietic Stem Cell Transplantation - adverse effects Hematopoietic stem cells Humans Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - therapy Male Medical sciences Medicin och hälsovetenskap Methotrexate - administration & dosage Methotrexate - adverse effects Middle Aged Patients Pharmacology. Drug treatments Risk Factors Spinal Puncture - adverse effects Stem cell transplantation Stem cells Tomography, X-Ray Computed
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Between 1990 and 1996, three patients (1.1%), all with CML, among 272 patients with haematological malignancies, developed bilateral subdural haematomas (SDH) after treatment with i.t. MTX before HSCT in our unit. Since October 1996, we have given i.t. MTX only to patients at increased risk of CNS leukaemia such as ALL and AML M4 or M5. We suggest that intrathecal treatment before HSCT should only be given to patients at increased risk of CNS leukaemia.
ISSN:	0268-3369 1476-5365
DOI:	10.1038/sj.bmt.1702018